Compare Cassava Sciences Inc (FLNA) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs ProShares Ultra QQQ ETF — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while ProShares Ultra QQQ ETF trades at $89.85. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | QLD | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $100.53 |
52-Week Low | $1.09 | $57.16 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
QLD, the ProShares Ultra QQQ ETF, is a 2x daily leveraged fund tracking the Nasdaq-100. The stock trades at $90.15, down 2.14% on the day, with a technical signal leaning bearish. Key financial ratios are not applicable for this ETF structure, which amplifies daily index returns. Recent news highlights its long-term performance and role in tactical portfolios, while technical analysis shows immediate support near $90.
The outlook hinges on the direction of the tech-heavy Nasdaq-100. The fund offers amplified exposure for tactical bullish bets but carries significant volatility and decay risks in sideways or declining markets. Its bearish technical signals and leveraged nature make it suitable only for investors with high risk tolerance and a short-term horizon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
